ClinicalTrials.gg
RecruitingNCT04185844AI-CRICUpdated Oct 13, 2026

American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)

An observational study in Diabetes Mellitus, Chronic Kidney Diseases and Heart Diseases, sponsored by University of New Mexico. Recruiting at 3 sites in United States. Open to participants aged 21 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of New Mexico · Observational

How we know

From the registry’s dates

  • Started Aug 2020; still recruiting 6 years 2 months later.
Updated Oct 13, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
504
Ages
21 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Diabetes Mellitus by University of New Mexico — 2 open to participants now, 2 under way, none of them phase 3. Diabetes Mellitus · University of New Mexico.

Started
2020
the only one that year
Observational
5 of 11
1 open now
Registered
9th of 11
by date

Among the 11 studies in Diabetes Mellitus by University of New Mexico, this one is the only one that started in 2020, is one of 5 observational ones, and was the 9th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 11 studies in Diabetes Mellitus by University of New Mexico are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 21 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes Mellitus by University of New Mexico, or all of them as a file.
02

Study summary

Despite many advances in our understanding of the natural history and progression of chronic kidney disease (CKD) and cardio vascular disease (CVD) in the parent CRIC study over the past 15 years, important questions about key risk factors for these diseases remain unanswered in the AI population. To address this burden of CKD in AI communities Investigators formed a consortium of investigators with extensive experience in conducting research of chronic diseases including diabetes, cardiovascular and kidney disease in AIs of Southwestern US. The proposed CRIC ancillary cohort study of 500 AIs (AI-CRIC) will rapidly improve our understanding of both potential risk factors for CKD progression, as well as the scope of this disease among AIs. This study leverages the current CRIC study and incorporates the planned activities of the next phase of the study - "CRIC 2018" - by implementing contemporary CRIC protocols for kidney and cardiovascular measurement and outcomes.

Read the detailed description

Investigators will conduct a longitudinal study of a CKD cohort of Southwest AIs to identify unique risk factors for CKD and CVD progression and compare CKD and CVD event rates and risk factors between AI and the populations represented in CRIC. Investigators will establish a specimen bank to support future ancillary studies designed to identify and examine biomarkers associated with the progression of CKD in AIs.

At the Clinic Visit the following will occur:

  • weight is measured
  • blood pressure and heart rate are recorded
  • information about medical history and medication used recently
  • blood draw (about ½ cup) for the following tests: CBC (Complete Blood Count), tests of metabolism, and several other heart and kidney tests
  • blood pressure in the leg and arm calculated as the Ankle Brachial Index (ABI)
  • urine sample collection for kidney function testing
  • complete questionnaires about quality of life, diet, mood, thought processes and physical activity.

This visit takes about 1 to 2 hours. Participants will be contacted by telephone six months after the Baseline Visit to ask about recent medical events and medications.

Participants will be asked to return to the center for annual visits during which many but not all of the procedures described above will be conducted.

Additionally, participants will be asked to participate in one of two substudies using remote data collection techniques to identify trajectories of kidney function and cardiovascular risk sub-phenotypes

03

Conditions studied

  • Diabetes Mellitus
  • Chronic Kidney Diseases
  • Heart Diseases
  • Cardiovascular Diseases
04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

American Indians at 3 sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (GFR): eGFR of =>61\<80 and microalbuminuria > 30 or eGRF of =\<60 (no microalbuminuria required).

Exclusion criteria

Exclusion Criteria:

  1. Unable or unwilling to provide
  2. \<3 years;
  3. institutionalized subjects;
  4. End stage renal disease or renal transplant;
  5. renal cancer;
  6. myeloma;
  7. ;
  8. Polycystic kidney disease;
  9. participation in any clinical trial,
  10. current pregnancy
  11. current incarceration.
  12. Appears unlikely or unable to participate in the required study procedures as assessed by the investigator, study coordinator or designee.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
504 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Slope of the GFR

    Primary outcomes regarding Cardio vascular disease will focus on clinical events indicative of ischemic heart disease, CHF, stroke, and peripheral vascular disease supplemented by radiographic evidence of progressive CVD.

    Time frame: 5 years

Secondary outcomes

  1. Onset of End Stage Renal Disease

    The measure is reflected in decline of GFR levels

    Time frame: 5 years

  2. Significant loss of renal function

    The measure is reflected in decline of GFR levels

    Time frame: 5 years

  3. Composite clinical outcome defined by the occurrence of either 50% decline, or 25 l/min/1.73 m2 decline in GFR from baseline, or onset of ESRD

    The composite clinical outcome includes onset of End Stage Renal Disease, Significant loss of renal function or changes in proteinuria over time from baseline

    Time frame: 5 years

  4. Slope of change in proteinuria over time

    The changes in the levels of proteinuria overtime

    Time frame: 5 years

07

Study locations

2 of 3 sites recruiting
  • NIDDK-Phoenix Epidemiology and Clinical Research
    Phoenix, Arizona 85016, United States
    Not yet recruiting
  • First Nations Community Health Source
    Albuquerque, New Mexico 87108, United States
    Recruiting
  • Zuni Health Initiative Center
    Black Rock, New Mexico 87327, United States
    Recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2020 (actual). Primary completion is estimated for Jul 2028, 95 months after the start.

Of 534 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 159. This study's planned 95 months is above that.

Counting every sponsor, half of 643 studies reached it within 36 months; a quarter within 14 and three quarters within 122.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jun 2028 → Jul 2028 and completion Jun 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2019
First posted
Dec 4, 2019
StartActual
Aug 31, 2020
Primary completionEst.
Jul 31, 2028was Jun 2028
CompletionEst.
Jul 31, 2028was Jun 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2028→Jul 31, 2028
Oct 13, 2026
Study completion
Jun 30, 2028→Jul 31, 2028
Oct 13, 2026
Enrollment
500→504
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Primary completion Jun 30, 2028→Jul 31, 2028
    Study completion Jun 30, 2028→Jul 31, 2028
    Enrollment 500→504
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04185844
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Aug 31, 2020
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Mark L Unruh, MD
Contact
MLUnruh@salud.unm.edu
505-272-8300
Mark L Unruh, MD
principal investigator · University of New Mexico

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion